{"id":"W4407285619","doi":"10.1093/jcag/gwae059.191","title":"A191 REAL WORLD USE OF ADALIMUMAB BIOSIMILAR AMGEVITA® (ABP-501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CANADA","year":2025,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Inflammatory bowel disease; Medicine; Inflammatory Bowel Diseases; Internal medicine; Disease; Gastroenterology; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004856331,0.0001444962,0.0002400171,0.0007362854,0.001462156,0.000991257,0.0005186946,0.0002833661,0.00173131],"category_scores_gemma":[0.002014267,0.000184245,0.0002738976,0.002595696,0.0005462278,0.0002378103,0.0004540438,0.0004735827,0.0001364655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01457136,"about_ca_system_score_gemma":0.01300447,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9725196,"about_ca_topic_score_gemma":0.9799626,"domain_scores_codex":[0.9989648,0.0001492052,0.00007870961,0.0001321171,0.0003803345,0.0002947882],"domain_scores_gemma":[0.9971871,0.0002747889,0.0008560611,0.00004000673,0.0007980908,0.0008440209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00006717743,0.00003175217,0.9958518,0.00003131462,0.00002001542,0.0001061898,0.0007048629,0.00004398697,0.0001202317,0.00002591821,0.0003931736,0.00260375],"study_design_scores_gemma":[0.000006140269,0.00004310669,0.9972837,0.00001814997,0.00001164488,0.00007119167,0.001876288,0.0001766843,0.00003922357,0.000005528738,0.0004615759,0.000006685385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965242,0.0003890011,0.00002852906,0.0002429512,0.00000326857,0.00001944168,0.001407827,0.000002814917,0.001381905],"genre_scores_gemma":[0.9991363,0.0001854584,0.00005503868,0.00007515639,0.000002961802,0.00000506274,0.0003648807,0.000001110236,0.0001740312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02748036,"threshold_uncertainty_score":0.1057231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005826618595907135,"score_gpt":0.2047474966732414,"score_spread":0.1989208780773342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}